EventsThe 2nd International Conference on Bioengineering
Published
This submission belongs to the session S4. Biomedical Engineering and Biomaterials of the event The 2nd International Conference on Bioengineering
Published date
16 Nov, 2026
Citation
Elisenda Santaló Ferrer, Enric Calucho Palma, Maria del Carmen Bermudo Redondo, Ciara Kathleen O'Sullivan, Victor Franco Puntes, Joan Comenge Farré, Claudio Parolo, Incorporation of nanomaterials into ELISA platforms, in Proceedings of The 2nd International Conference on Bioengineering, Barcelona, 10 November–13 November 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Incorporation of nanomaterials into ELISA platforms

Enric Calucho Palma 1
Maria del Carmen Bermudo Redondo 1
Claudio Parolo 1,6
1. Chemical Engineering Department, Universitat Rovira i Virgili, Tarragona, 43007, Spain
2. Institució Catalana de Recerca i Estudis Avançats (ICREA), Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, 08010, Spain
3. Vall Hebron Institut de Recerca, Hospital Vall Hebron , Barcelona, 08035, Spain
4. Networking Research Centre for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, 28029, Spain
5. Institut Català de Nanociència i Nanotecnologia (ICN2), Universitat Autònoma de Barcelona, Barcelona, 08193 , Spain
6. ISGlobal, ISGlobal, Barcelona, 08036, Spain
Abstract

This work explores the incorporation of nanomaterials into enzyme-linked immunosorbent assays (ELISAs) as a strategy to enhance the analytical performance, versatility, and accessibility of contemporary molecular diagnostic platforms. Nanomaterials, including metallic and polymeric nanoparticles, quantum dots, nanozymes, and plasmonic systems, exhibit distinctive optical, electronic, and catalytic properties that can be exploited to improve biomolecular recognition, signal generation, signal amplification and assay performance. Their integration into ELISA-based systems can therefore increase detection sensitivity, extend dynamic range, reduce detection limits, and enable quantitative and multiplexed analysis of clinically relevant biomarkers. ELISA technique remain the gold standard for biomarker detection owing to its robustness, reproducibility, and compatibility with diverse biological samples. The incorporation of nanomaterials into conventional ELISA architectures provides an opportunity to overcome some of the limitations associated with traditional colorimetric detection while preserving the reliability and practical advantages of the technique. These developments are particularly relevant to the advancement of precision medicine, where highly sensitive and accurate biomarker quantification is essential for early disease detection, patient stratification, therapeutic monitoring, and individualized clinical decision-making. Beyond improvements in analytical performance, nanomaterial-enabled ELISA platforms also offer considerable potential for adaptation to diverse diagnostic environments. Their compatibility with miniaturized, portable, and low-cost detection formats may facilitate the transition from centralized laboratory testing toward decentralized diagnostic settings. Overall, nanomaterial-enhanced ELISAs represent a promising approach for the development of innovative diagnostic platforms that combine the established reliability of conventional immunoassays with the advanced physicochemical properties of nanomaterials.

Keywords
ELISA
Nanomaterials
Decentralized diagnostic settings
Biomarker detection
Electric fields to stimulate the three-dimensional migration of transplantable donor cells in retina
Engineering an Explainable Decision-Support Pipeline for Automated Blood Gas Interpretation